New associations between COVID-19 and immune responses in cancer patients reveal potential inroads to fighting tumours.
A T cell therapy innovation may offer new hope for acute myeloid leukemia patients who relapse after conventional treatment.
Imaging experts discover a non-invasive method to identify which patients with liver cancer are most likely to respond to immunotherapy.
A*STAR researchers discover a mechanism that fires up the metabolism of cancer-killing immune cells, paving the way for future cancer immunotherapies.
Researchers engineer specialized T cells that can transiently and effectively attack liver cancer cells even in the presence of immunosuppressive drugs.
A new biomarker in liver tumor may help doctors predict how patients respond to immunotherapy.
A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.
Just because a molecular target resides inside a cancer cell does not mean that it cannot be targeted by antibodies, says Qi Zeng, founder of A*STAR spin-off company Intra-ImmuSG.
Virus-targeting white blood cells in tumors offer intriguing insights into responsiveness to immunotherapy
Generating large numbers of universal immune cells could transform cancer immunotherapy
Alterations in gene
regulation make gastric cancer cells less visible to the immune system